Expand KYTX Menu
KYTX MENU

KYTX Stock Summary and Trading Ideas (Kyverna Therapeutics | NASDAQ:KYTX)

Charts for Today's Stock Price and Implied Volatility in Kyverna Therapeutics

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for KYTX by Theoretical Edge and Win Rates

Sentiment

News

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors

Business Wire (Mon, 16-Dec 12:03 PM ET)

Kirby McInerney LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Globe Newswire (Mon, 16-Dec 8:00 AM ET)

KYTX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Business Wire (Mon, 16-Dec 6:01 AM ET)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX

PRNewswire (Mon, 16-Dec 5:45 AM ET)

KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Business Wire (Sun, 15-Dec 4:00 PM ET)

KYTX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Globe Newswire (Sun, 15-Dec 10:55 AM ET)

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action KYTX

Globe Newswire (Sat, 14-Dec 12:06 PM ET)

Kyverna Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the KYTX Class Action Lawsuit

Globe Newswire (Fri, 13-Dec 4:18 PM ET)

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

PRNewswire (Fri, 13-Dec 4:05 PM ET)

DEADLINE ALERT for BOOM, KYTX, and MQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Globe Newswire (Fri, 13-Dec 12:18 PM ET)

Trading Statistics

Key Ratios

Kyverna Therapeutics (KYTX) Frequently Asked Questions

What does Kyverna Therapeutics do?

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

What symbol and exchange does Kyverna Therapeutics shares trade?

Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.

What is Kyverna Therapeutics stock price doing today?

As of December 16, 2024, KYTX stock price was flat at $4.42 with 97,681 million shares trading.

What is Kyverna Therapeutics's Beta?

KYTX has a beta of 1.96, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.07 to the broad based SPY ETF.

How much is Kyverna Therapeutics worth?

KYTX has a market cap of $190.82 million. This is considered a Micro Cap stock.

What are the top ETFs holding Kyverna Therapeutics?

The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IWM, VXF, SCHA, IWO.

What are the support and resistance levels for Kyverna Therapeutics (KYTX)?

KYTX support price is $4.08 and resistance is $4.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.